

FROM :

FAX NO. :6104379150

Feb. 11 2008 01:49PM P1

PTO/SB/21 (09-08)

Approved for use through 03/31/2007. OMB 0651-0031


U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/510,677	
	Filing Date	10/06/2004	
	First Named Inventor	M. Parrington	
	Art Unit	1642	
	Examiner Name	Sean E. Aeder	
Total Number of Pages in This Submission	18	Attorney Docket Number	API-01-20-US

RECEIVED
CENTRAL FAX CENTER
FEB 11 2008

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Please see "Remarks" section.
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Reply to Missing Parts/Incomplete Application	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	Remarks Submitted via facsimile to 571-273-8300 Attached: Information Disclosure Statement (2 pages); PTO/SB/08A (1 page); PTO/SB/08B (1 page); Beauchemin et al. (10 pages); Kim et al. (2 pages); Marshall et al. (2 pages)	

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name	Patrick J. Halloran, Ph.D., J.D.		
Signature			
Printed name	Patrick J. Halloran		
Date	02/11/2008	Reg. No.	41,053

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:			
Signature			
Typed or printed name	Patrick J. Halloran	Date	02/11/2008

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

RECEIVED
CENTRAL FAX CENTER**FEB 11 2008****PATENT****IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**
(API-01-20-US)**In Re Application of:****Parrington, et al****Serial No.: 10/510, 677****Filing Date: 09 APRIL 2003****Title: MODIFIED CEA NUCLEIC ACID AND
EXPRESSION VECTORS****)**
)
) Examiner: Sean E. Aeder
)
)
) Group Art Unit: 1642
)
)
)
)**Commissioner for Patents**
P.O. Box 1450
Alexandria, VA 22313-1450**Submitted via facsimile to 571-273-8300****To the Examiner:**

Applicants respectfully submit this Supplemental Information Disclosure Statement, PTO-1449 and copies of the reference cited therein. Applicants do not believe any fees are due with this submission. If this is in error, the undersigned hereby authorizes the Commissioner to deduct any required fees from Deposit Account No. 50-0244. This Information Disclosure Statement is in compliance with the duty of candor as set forth in 37 C.F.R. § 1.56. It is requested that the documents be given careful consideration and that they be cited of record in the prosecution history of the present application so that they will appear on the face of the patent issuing of the present application.

In the judgment of the undersigned, portions of the references may be material to the examination of the pending claims. However, the references have not been reviewed in sufficient detail to make any other representation and, in particular, no representation is intended as to the relative importance of any portion of the references. This Statement is not a representation that the cited references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. §102 or §103.

RECEIVED
CENTRAL FAX CENTER

FEB 11 2008

CITED REFERENCESU.S. Patent Documents

US 2003/003079A1

US 5,990,091

Non-Patent Documents

Beauchemin, et al. Isolation and Characterization of Full-Length Functional cDNA Clones for Human Carcinoembryonic Antigen. Mol. Cell. Biol., Sept. 1987, pp. 3221-3230


DATABASE EMBL [Online] 9 March 2002 (2002-03-09), "K-EST0028539 S9SNU601 Homo sapiens cDNA clone S9SNU601-4-E04 5', mRNA sequence." retrieved from EBI accession no. EM_EST:BM752131 Database accession no. BM752131.

Marshall, et al. A phase I study of sequential vaccinations with fowlpox-CEA(6D)-Tricom (B7/ICAM/LFA3) alone, and in combination with vaccinia-CEA(6D)-Tricom and GM-CSF in patients with CEA-expressing carcinomas. Abstract No. 24. 2002 ASCO Annual Meeting.

Respectfully Submitted,

Date: February 11, 2008

By:


Patrick J. Halloran
Reg. No. 41,053

Patrick J. Halloran, Ph.D., J.D.
3141 Muirfield Road
Center Valley, PA 18034
Tel: 610-984-4751
Fax: 484-214-0164